Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Doxil Availability Once Again in Question

October 9th 2013

Access to Doxil has been inconsistent since mid-2011, when the drug's sole manufacturer announced a voluntary shutdown of production to address significant manufacturing and quality concerns.

Dr. Burger on Bevacizumab in Ovarian Cancer

October 9th 2013

Robert A. Burger, MD, FACOG, FACS, Professor, Department of Surgical Oncology, Director, Women's Cancer Center, Fox Chase Cancer Center, discusses the use of bevacizumab in patients with ovarian cancer.

Verastem Targets Cancer Stem Cells

October 8th 2013

Cancer stem cells are an underlying cause of a tumor's ability to recur and metastasize even after initial treatment. Therefore, targeting those cancer stem cells could prove to be a valuable tool in the treatment of several different tumor types.

Dr. Thigpen on Comparing Treatments in Ovarian Cancer

October 7th 2013

James "Tate" T. Thigpen, MD, Professor of Medicine, Director, Division of Medical Oncology, University of Mississippi School of Medicine, discusses the comparison of treatment options in ovarian cancer.

Trebananib Shows Promise in Recurrent Platinum-Sensitive Ovarian Cancer

October 3rd 2013

Trebananib added to paclitaxel significantly improved progression-free survival in patients with recurrent ovarian cancer compared with placebo plus paclitaxel in the large international TRINOVA-1 trial.

Dr. Markman on Targets for the Treatment of Ovarian Cancer

September 30th 2013

Maurie Markman, MD, from the Cancer Treatment Centers of America, discusses the discovery of mutations and targets in ovarian cancer and the current progress being made in the development of a "breakthrough" agent for ovarian cancer.

Gynecologic Cancers Symposium Puts Emphasis on Unsettled Questions

September 27th 2013

Hot topics, emerging therapies, and tough cases from the front lines of patient care will be featured during the 9th Annual International Symposium on Ovarian Cancer and Gynecologic Malignancies, scheduled for October 5 in Philadelphia.

Alvarez Plays Leadership Role in Gynecologic Cancer Field

September 20th 2013

Whether it involves the minutiae of preclinical studies or the broad perspective of group leadership, if the work concerns gynecologic oncology, Ronald D. Alvarez, MD, has likely tried it.

Dr. Aghajanian on Ovarian Cancer Trial Endpoints

September 16th 2013

Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses the difficulties with a gold standard clinical trial endpoint in ovarian cancer.

Research Team in Canada Explores PARP's Complex Role in DNA Repair

September 9th 2013

Recently, Girish M. Shah's team has been using cellular and murine models to examine various therapeutic options, including inhibitor and gene knockout approaches against the DNA damage-responsive enzyme poly(ADP-ribose) polymerase 1 (PARP-1).

Dr. Garcia on the Future Role of PARP inhibitors

September 9th 2013

Agustin A. Garcia, MD, associate professor of medicine, Keck School of Medicine of the University of Southern California, discusses the future role of PARP inhibitors for patients with ovarian cancer and breast cancer.

Maintenance Olaparib Resurrected for Phase III Program

September 4th 2013

The first patient has been enrolled in a phase III clinical program investigating treatment with olaparib for patients with BRCA-mutated ovarian cancer, marking another step in the revived development of an agent once relegated to the sidelines.

CA-125 Monitoring Shows Benefit in Early Detection of Ovarian Cancer

August 26th 2013

A two-pronged approach that includes carbohydrate antigen 125 (CA-125) testing proved highly accurate in screening women for ovarian cancer, including aggressive forms of the disease.

Ovarian Cancer Chemoresponse Assay Demonstrates Utility

August 20th 2013

The use of a chemoresponse assay to assess therapy choices for patients with recurrent ovarian cancer correlated with dramatic improvements in overall survival and progression-free survival.

Nearly Two-Thirds of Ovarian Cancer Patients Not Receiving NCCN-Recommended Treatment

July 18th 2013

An analysis of more than 13,000 patients with ovarian cancer found that only around 37% of patients receive care that adheres to the NCCN guidelines.

IP Chemo Improves Long-Term Survival in Ovarian Cancer

July 15th 2013

Women with advanced ovarian cancer lived almost a year longer when treated with intraperitoneal chemotherapy instead of intravenous therapy.

Research Spotlight: Promising Phase I Results

July 12th 2013

Highlights of key findings from several phase I clinical trials that provide insight into new and emerging druggable targets and targeted therapies.

Novel Two-Step Immunotherapy Shows Promise in Early-Stage Ovarian Cancer Study

July 9th 2013

A two-step immunotherapy approach consisting of adoptive T-cell therapy and a dendritic cell vaccine has shown activity in a phase I advanced ovarian cancer clinical trial.

Dr. Aghajanian on PARP Inhibitors for Ovarian Cancer

July 3rd 2013

Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses the treatment of ovarian cancer with PARP inhibitors.

PARP Inhibitor Active in Recurrent BRCA-Mutant Ovarian Cancer

June 28th 2013

A dual-action PARP inhibitor has shown sufficient clinical activity to continue its investigation in women with recurrent BRCA-mutant ovarian cancer.